Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Maze Therapeutics (MAZE) EPS (Weighted Average and Diluted) (2024 - 2025)

Maze Therapeutics has reported EPS (Weighted Average and Diluted) over the past 2 years, most recently at -$0.6 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 57.75% to -$0.6 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.18 through Dec 2025, up 85.78% year-over-year, with the annual reading at -$3.05 for FY2025, 344.0% down from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.6 for Q4 2025 at Maze Therapeutics, up from -$0.66 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $3.22 in Q2 2024 and troughed at -$13.91 in Q1 2024.